Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 7
2006 5
2007 9
2008 2
2009 2
2010 6
2011 4
2012 3
2013 3
2014 5
2015 3
2016 5
2017 4
2018 8
2019 1
2020 25
2021 27
2022 20
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis.
Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegadlo-Mylik MA, Pulka G, Dmowska-Stecewicz M, Kłujszo E, Rekalov D, Rajzer L, Lee J, Lee M, Rho YH. Feldman SR, et al. Among authors: narbutt j. J Am Acad Dermatol. 2024 Apr 27:S0190-9622(24)00663-7. doi: 10.1016/j.jaad.2024.04.045. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38685404
Does the effectiveness of biological medications in the treatment for psoriasis depend on the moment of starting therapy? A preliminary study.
Niedźwiedź M, Noweta M, Narbutt J, Owczarek W, Ciążyńska M, Czerwińska A, Krzyścin J, Lesiak A, Skibińska M. Niedźwiedź M, et al. Among authors: narbutt j. Postepy Dermatol Alergol. 2024 Feb;41(1):106-112. doi: 10.5114/ada.2024.135917. Epub 2024 Feb 28. Postepy Dermatol Alergol. 2024. PMID: 38533365 Free PMC article.
Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation.
Niedźwiedź M, Narbutt J, Siekierko A, Skibińska M, Kwiek B, Sobolewska-Sztychny D, Ciążyńska M, Poznańska-Kurowska K, Gostyński A, Lesiak A. Niedźwiedź M, et al. Among authors: narbutt j. Front Med (Lausanne). 2024 Feb 5;11:1360248. doi: 10.3389/fmed.2024.1360248. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38375322 Free PMC article.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Papp KA, Lebwohl MG, Thaçi D, Jaworski J, Kwiek B, Trefler J, Dudek A, Szepietowski JC, Reznichenko N, Narbutt J, Baran W, Kolinek J, Daniluk S, Bartnicka-Maslowska K, Reich A, Andrashko Y, Kim S, Bae Y, Jeon D, Jung J, Lee H, Pyo T, Ko W. Papp KA, et al. Among authors: narbutt j. BioDrugs. 2024 Jan;38(1):121-131. doi: 10.1007/s40259-023-00630-5. Epub 2023 Nov 22. BioDrugs. 2024. PMID: 37991693 Free PMC article. Clinical Trial.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Does molecular scarring in psoriasis exist? A review of the literature.
Kasprowicz-Furmańczyk M, Narbutt J, Borzęcki A, Owczarczyk-Saczonek A. Kasprowicz-Furmańczyk M, et al. Among authors: narbutt j. Postepy Dermatol Alergol. 2023 Aug;40(4):473-480. doi: 10.5114/ada.2023.129322. Epub 2023 Jul 6. Postepy Dermatol Alergol. 2023. PMID: 37692280 Free PMC article. Review.
150 results